1. Home
  2. XTLB vs AIM Comparison

XTLB vs AIM Comparison

Compare XTLB & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XTLB
  • AIM
  • Stock Information
  • Founded
  • XTLB 1993
  • AIM 1966
  • Country
  • XTLB Israel
  • AIM United States
  • Employees
  • XTLB N/A
  • AIM N/A
  • Industry
  • XTLB Biotechnology: Pharmaceutical Preparations
  • AIM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • XTLB Health Care
  • AIM Health Care
  • Exchange
  • XTLB Nasdaq
  • AIM Nasdaq
  • Market Cap
  • XTLB 16.3M
  • AIM 15.9M
  • IPO Year
  • XTLB 2005
  • AIM N/A
  • Fundamental
  • Price
  • XTLB $1.85
  • AIM $0.23
  • Analyst Decision
  • XTLB
  • AIM Strong Buy
  • Analyst Count
  • XTLB 0
  • AIM 2
  • Target Price
  • XTLB N/A
  • AIM $2.75
  • AVG Volume (30 Days)
  • XTLB 13.9K
  • AIM 667.3K
  • Earning Date
  • XTLB 02-21-2025
  • AIM 11-15-2024
  • Dividend Yield
  • XTLB N/A
  • AIM N/A
  • EPS Growth
  • XTLB N/A
  • AIM N/A
  • EPS
  • XTLB N/A
  • AIM N/A
  • Revenue
  • XTLB $46,000.00
  • AIM $190,000.00
  • Revenue This Year
  • XTLB N/A
  • AIM N/A
  • Revenue Next Year
  • XTLB N/A
  • AIM $1,693.10
  • P/E Ratio
  • XTLB N/A
  • AIM N/A
  • Revenue Growth
  • XTLB N/A
  • AIM N/A
  • 52 Week Low
  • XTLB $0.77
  • AIM $0.16
  • 52 Week High
  • XTLB $4.99
  • AIM $0.62
  • Technical
  • Relative Strength Index (RSI)
  • XTLB 50.05
  • AIM 55.31
  • Support Level
  • XTLB $1.66
  • AIM $0.19
  • Resistance Level
  • XTLB $1.85
  • AIM $0.23
  • Average True Range (ATR)
  • XTLB 0.22
  • AIM 0.02
  • MACD
  • XTLB -0.02
  • AIM 0.00
  • Stochastic Oscillator
  • XTLB 45.83
  • AIM 64.29

About XTLB XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

About AIM AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Share on Social Networks: